Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$2.36 USD
-0.15 (-5.98%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $2.36 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AYTU 2.36 -0.15(-5.98%)
Will AYTU be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AYTU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AYTU
Agilent Technologies (A) Surpasses Q3 Earnings and Revenue Estimates
AYTU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AYTU
Aytu BioPharma to Present at Upcoming October 2025 Conferences
The technical outlook for AYTU is unchanged after it rises 5.91% on October 9
AYTU rises 0.42% on October 8, leaving the technical picture intact
AYTU Crossed Above 50 Day Moving Average on October 7
Aytu BioPharma management to meet with Lake Street